Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 5/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 5/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | RECQL | P46063 | 5/20 | 1.00 |
| ▸ | BLM | P54132 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6055311 | 1.00 | EGFR (1.00) | EGFRKDM4EMEN1ALDH1A1CYP3A4 | |
| SCHEMBL29376415 | 1.00 | EGFR (1.00) | EGFRKDM4EMEN1ALDH1A1CYP3A4 | |
| SCHEMBL3486952 | 1.00 | EGFR (1.00) | EGFRKDM4EMEN1ALDH1A1CYP3A4 | |
| SCHEMBL645290 | 0.97 | EGFR (1.00) | EGFRKDM4EMEN1ALDH1A1CYP3A4 | |
| SCHEMBL29378814 | 0.97 | EGFR (1.00) | EGFRKDM4EMEN1ALDH1A1CYP3A4 | |
| SCHEMBL645291 | 0.97 | EGFR (1.00) | EGFRKDM4EMEN1ALDH1A1CYP3A4 | |
| SCHEMBL7378564 | 0.92 | EGFR (1.00) | EGFRKDM4EMEN1ALDH1A1CYP3A4 | |
| SCHEMBL6213511 | 0.89 | EGFR (1.00) | EGFRKDM4EMEN1ALDH1A1CYP3A4 | |
| SCHEMBL6213506 | 0.89 | EGFR (1.00) | EGFRKDM4EMEN1ALDH1A1CYP3A4 | |
| SCHEMBL13184692 | 0.89 | EGFR (0.80) | EGFRKDM4EMEN1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| WO-2024102187-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | PINETREE THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | claimed |
| CN-112839649-B | CXCR4 inhibitor compositions and methods of making and using the same | X4 制药有限公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026087699-A1 | NEW TREATMENT OF NON-SMALL CELL LUNG CANCER | PIERRE FABRE MEDICAMENT (FR) | 2026-04-30 | — | — | WO | disclosed |
| EP-4705302-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4705300-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4705301-A2 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250340548-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORP (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250262213-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2025-08-21 | — | — | US | disclosed |
| US-12336995-B2 | Combination therapies | Mirati Therapeutics, Inc. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20140328940-A1 | MODULATION OF AXON DEGENERATION | GENENTECH, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140328940-A1 | MODULATION OF AXON DEGENERATION | GENENTECH, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140328940-A1 | MODULATION OF AXON DEGENERATION | GENENTECH, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8569481-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120328609-A1 | Modulation of Axon Degeneration | GENENTECH, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120328609-A1 | Modulation of Axon Degeneration | GENENTECH, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120328609-A1 | Modulation of Axon Degeneration | GENENTECH, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20110256150-A1 | Modulation of Axon Degeneration | GENENTECH, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-7858560-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140328940-A1 | MODULATION OF AXON DEGENERATION | GAP43, NLN, BDNF | EGFR 3710/4885KDM4E 3990/4885MEN1 4535/4885 |
| US-20120328609-A1 | Modulation of Axon Degeneration | GAP43, NLN, BDNF | EGFR 3710/4885KDM4E 3990/4885MEN1 4535/4885 |
| US-20250262213-A1 | COMBINATION THERAPIES | KRAS, NRAS, HRAS | EGFR 4/4885KDM4E 4179/4885MEN1 298/4885 |
| US-20250340548-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | EGFR 176/4885KDM4E 3048/4885MEN1 721/4885 |
| US-12336995-B2 | Combination therapies | KRAS, NRAS, HRAS | EGFR 4/4885KDM4E 4374/4885MEN1 439/4885 |
| US-20110256150-A1 | Modulation of Axon Degeneration | GAP43, NLN, BDNF | EGFR 3710/4885KDM4E 3990/4885MEN1 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.